Background: The amyloidoses are a rare and heterogeneous group of disorders that are characterized by the deposition of abnormally folded proteins in tissues ultimately leading to organ damage. The deposits are mainly extracellular and are recognizable by their affinity for Congo red and their yellow-green birefringence under polarized light. Current classification of amyloid in medical practice is based on the amyloid protein type. To date, 36 proteins have been identified as being amyloidogenic in humans. Summary: in clinical practice, it is critical to distinguish between treatable versus non-treatable amyloidoses. Moreover, amyloidoses with a genetic component must be distinguished from the sporadic types and systemic amyloidoses must be distinguished from the localized forms. Among the systemic amyloidoses, AL continues to be the most common amyloid diagnosis in the developed world; other clinically significant types include AA, ALECT2, and ATTR. The latter is emerging as an underdiagnosed type in both the hereditary and wild-type setting. Other hereditary amyloidoses include AFib, several amyloidoses derived from apolipoproteins, AGel, ALys, etc. In a dialysis setting, systemic amyloid derived from β2 microglobulin (Aβ2M) should be considered, although a very rare hereditary variant has also been reported; several amyloidoses may be typically associated with aging and several iatrogenic types have also emerged. Determination of the amyloid protein type is imperative before specific therapy can be implemented and the current methods are briefly summarized. A brief overview of the target organ involvement by amyloid type is also included. Key Messages: (1) Early diagnosis of amyloidosis continues to pose a significant challenge and requires the participation of many clinical and laboratory specialties. (2) Determination of the protein type is imperative before specific therapy can be implemented. (3) While mass spectrometry has emerged as the preferred method of amyloid typing, careful application of immune methods is still clinically useful but caution and experience, as well as awareness of the limitations of each method, are necessary in their interpretation. (4) While the spectrum of amyloidoses continues to expand, it is critical to distinguish between those that are currently treatable versus those that are untreatable and avoid causing harm by inappropriate treatment.

1.
Benson
MD
,
Buxbaum
JN
,
Eisenberg
DS
,
Merlini
G
,
Saraiva
MJ
,
Sekijima
Y
, et al.
Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee
.
Amyloid
.
2018
Dec
;
25
(
4
):
215
9
.
[PubMed]
1350-6129
2.
Chiti
F
,
Dobson
CM
.
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
.
Annu Rev Biochem
.
2017
Jun
;
86
(
1
):
27
68
.
[PubMed]
0066-4154
3.
Nuvolone
M
,
Merlini
G
.
Systemic amyloidosis: novel therapies and role of biomarkers
.
Nephrol Dial Transplant
.
2017
May
;
32
(
5
):
770
80
.
[PubMed]
1460-2385
4.
Misra
P
,
Blancas-Mejia
LM
,
Ramirez-Alvarado
M
.
Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains
.
Biochemistry
.
2019
Jul
;
58
(
29
):
3155
68
.
[PubMed]
0006-2960
5.
Wechalekar
AD
,
Gillmore
JD
,
Hawkins
PN
.
Systemic amyloidosis
.
Lancet
.
2016
Jun
;
387
(
10038
):
2641
54
.
[PubMed]
0140-6736
6.
Gertz
MA
.
Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment
.
Am J Hematol
.
2018
Sep
;
93
(
9
):
1169
80
.
[PubMed]
0361-8609
7.
Merlini
G
,
Dispenzieri
A
,
Sanchorawala
V
,
Schönland
SO
,
Palladini
G
,
Hawkins
PN
, et al.
Systemic immunoglobulin light chain amyloidosis
.
Nat Rev Dis Primers
.
2018
Oct
;
4
(
1
):
38
.
[PubMed]
2056-676X
8.
Gertz
MA
,
Mauermann
ML
,
Grogan
M
,
Coelho
T
.
Advances in the treatment of hereditary transthyretin amyloidosis: A review
.
Brain Behav
.
2019
Sep
;
9
(
9
):
e01371
.
[PubMed]
2162-3279
9.
Maurer
MS
,
Bokhari
S
,
Damy
T
,
Dorbala
S
,
Drachman
BM
,
Fontana
M
, et al.
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis
.
Circ Heart Fail
.
2019
Sep
;
12
(
9
):
e006075
.
[PubMed]
1941-3289
10.
Adams
D
,
Ando
Y
,
Beirão
JM
,
Coelho
T
,
Gertz
MA
,
Gillmore
JD
, et al.
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
.
[Epub ahead of print] [ Review]
.
J Neurol
.
2020
Jan
;
•••
:
[PubMed]
0340-5354
11.
Picken
MM
.
Alect2 amyloidosis: primum non nocere (first, do no harm)
.
Kidney Int
.
2014
Aug
;
86
(
2
):
229
32
.
[PubMed]
0085-2538
12.
Naiki
H
,
Sekijima
Y
,
Ueda
M
, et al.
Human Amyloidosis, Still Intractable but Becoming Curable: The Essential Role of Pathological Diagnosis in the Selection of Type-Specific Therapeutics. Pathol Int
2020
Jan 21[Online ahead of print] PMID: 31961039 DOI:
13.
Quock
TP
,
Yan
T
,
Chang
E
,
Guthrie
S
,
Broder
MS
.
Epidemiology of AL amyloidosis: a real-world study using US claims data
.
Blood Adv
.
2018
May
;
2
(
10
):
1046
53
.
[PubMed]
2473-9529
14.
Gertz
MA
,
Comenzo
R
,
Falk
RH
,
Fermand
JP
,
Hazenberg
BP
,
Hawkins
PN
, et al.
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
.
Am J Hematol
.
2005
Aug
;
79
(
4
):
319
28
.
[PubMed]
0361-8609
15.
Ombrello
AK
,
Aksentijevich
IA
. Amyloidosis. In: Amyloid and related disorders – surgical pathology and clinical correlations, 2nd ed. Humana Press
2015
, Ed: Picken MM, Herrera GA, Dogan A. pp 31-53.
16.
Westermark
GT
,
Fändrich
M
,
Westermark
P
.
AA amyloidosis: pathogenesis and targeted therapy
.
Annu Rev Pathol
.
2015
;
10
(
1
):
321
44
.
[PubMed]
1553-4006
17.
Lane
T
,
Pinney
JH
,
Gilbertson
JA
,
Hutt
DF
,
Rowczenio
DM
,
Mahmood
S
, et al.
Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre
.
Amyloid
.
2017
Sep
;
24
(
3
):
162
6
.
[PubMed]
1350-6129
18.
Papa
R
,
Lachmann
HJ
.
Secondary, AA, Amyloidosis
.
Rheum Dis Clin North Am
.
2018
Nov
;
44
(
4
):
585
603
.
[PubMed]
0889-857X
19.
Larsen
CP
,
Ismail
W
,
Kurtin
PJ
,
Vrana
JA
,
Dasari
S
,
Nasr
SH
.
Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians
.
Mod Pathol
.
2016
Apr
;
29
(
4
):
416
20
.
[PubMed]
0893-3952
20.
Blank
N
,
Hegenbart
U
,
Dietrich
S
,
Brune
M
,
Beimler
J
,
Röcken
C
, et al.
Obesity is a significant susceptibility factor for idiopathic AA amyloidosis
.
Amyloid
.
2018
Mar
;
25
(
1
):
37
45
.
[PubMed]
1350-6129
21.
Said
SM
,
Sethi
S
,
Valeri
AM
,
Leung
N
,
Cornell
LD
,
Fidler
ME
, et al.
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases
.
Clin J Am Soc Nephrol
.
2013
Sep
;
8
(
9
):
1515
23
.
[PubMed]
1555-9041
22.
Larsen
CP
,
Beggs
ML
,
Wilson
JD
,
Lathrop
SL
. Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico Amyloid
2016
; 23(2): 119-123
23.
Benson
MD
,
James
S
,
Scott
K
,
Liepnieks
JJ
,
Kluve-Beckerman
B
.
Leukocyte chemotactic factor 2: A novel renal amyloid protein
.
Kidney Int
.
2008
Jul
;
74
(
2
):
218
22
.
[PubMed]
0085-2538
24.
Hutton
HL
,
DeMarco
ML
,
Magil
AB
,
Taylor
P
.
Renal leukocyte chemotactic factor 2 (LECT2) amyloidosis in First Nations people in Northern British Columbia, Canada: a report of 4 cases
.
Am J Kidney Dis
.
2014
Nov
;
64
(
5
):
790
2
.
[PubMed]
0272-6386
25.
Rezk
T
,
Gilbertson
JA
,
Rowczenio
D
,
Bass
P
,
Lachmann
HJ
,
Wechalekar
AD
, et al.
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis
.
Nephrol Dial Transplant
.
2018
Feb
;
33
(
2
):
241
7
.
[PubMed]
1460-2385
26.
Said
SM
,
Sethi
S
,
Valeri
AM
,
Chang
A
,
Nast
CC
,
Krahl
L
, et al.
Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis
.
Kidney Int
.
2014
Aug
;
86
(
2
):
370
7
.
[PubMed]
0085-2538
27.
Nasr
SH
,
Dogan
A
,
Larsen
CP
.
Leukocyte cell–derived chemotaxin 2–associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics
.
Clin J Am Soc Nephrol
.
2015
Nov
;
10
(
11
):
2084
93
.
[PubMed]
1555-9041
28.
Benson
MD
. The Hereditary Amyloidoses. In: Amyloid and related disorders – surgical pathology and clinical correlations, 2nd ed. Humana Press
2015
, Ed: Picken MM, Herrera GA, Dogan A. pp 65-80.
29.
Maurer
MS
,
Hanna
M
,
Grogan
M
,
Dispenzieri
A
,
Witteles
R
,
Drachman
B
, et al.;
THAOS Investigators
.
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)
.
J Am Coll Cardiol
.
2016
Jul
;
68
(
2
):
161
72
.
[PubMed]
0735-1097
30.
Parman
Y
,
Adams
D
,
Obici
L
,
Galán
L
,
Guergueltcheva
V
,
Suhr
OB
, et al.;
European Network for TTR-FAP (ATTReuNET)
.
Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP
.
Curr Opin Neurol
.
2016
Feb
;
29
Suppl 1
:
S3
13
.
[PubMed]
1350-7540
31.
Rubin
J
,
Maurer
MS
.
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable
.
Annu Rev Med
.
2020
Jan
;
71
(
1
):
203
19
.
[PubMed]
0066-4219
32.
Gillmore
JD
,
Lachmann
HJ
,
Rowczenio
D
,
Gilbertson
JA
,
Zeng
CH
,
Liu
ZH
, et al.
Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis
.
J Am Soc Nephrol
.
2009
Feb
;
20
(
2
):
444
51
.
[PubMed]
1046-6673
33.
Stangou
AJ
,
Banner
NR
,
Hendry
BM
,
Rela
M
,
Portmann
B
,
Wendon
J
, et al.
Hereditary fibrinogen A α-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation
.
Blood
.
2010
Apr
;
115
(
15
):
2998
3007
.
[PubMed]
0006-4971
34.
Jacobson
DR
,
Alexander
AA
,
Tagoe
C
,
Buxbaum
JN
.
Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans
.
Amyloid
.
2015
;
22
(
3
):
171
4
.
[PubMed]
1350-6129
35.
Suhr
OB
,
Lundgren
E
,
Westermark
P
.
One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition
.
J Intern Med
.
2017
Apr
;
281
(
4
):
337
47
.
[PubMed]
0954-6820
36.
Phull
P
,
Sanchorawala
V
,
Connors
LH
,
Doros
G
,
Ruberg
FL
,
Berk
JL
, et al.
Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)
.
Amyloid
.
2018
Mar
;
25
(
1
):
62
7
.
[PubMed]
1350-6129
37.
Picken
MM
.
Fibrinogen amyloidosis: the clot thickens!
Blood
.
2010
Apr
;
115
(
15
):
2985
6
.
[PubMed]
0006-4971
38.
Tavares
I
,
Moraira
L
,
Costa
PP
,
Lobato
L
.
Fibrinogen A alpha chain amyloidosis: a non-negligible cause of chronic kidney disease in dialysis patients.
Amyloid
2017
; 24(sup 1), 153-154.
39.
Chapman
J
,
Dogan
A
.
Fibrinogen alpha amyloidosis: insights from proteomics
.
Expert Rev Proteomics
.
2019
Sep
;
16
(
9
):
783
93
.
[PubMed]
1478-9450
40.
Valleix
S
,
Drunat
S
,
Philit
JB
,
Adoue
D
,
Piette
JC
,
Droz
D
, et al.
Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family
.
Kidney Int
.
2002
Mar
;
61
(
3
):
907
12
.
[PubMed]
0085-2538
41.
Grogan
M
,
Scott
CG
,
Kyle
RA
,
Zeldenrust
SR
,
Gertz
MA
,
Lin
G
, et al.
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System
.
J Am Coll Cardiol
.
2016
Sep
;
68
(
10
):
1014
20
.
[PubMed]
0735-1097
42.
Brunjes
DL
,
Castano
A
,
Clemons
A
,
Rubin
J
,
Maurer
MS
.
Transthyretin Cardiac Amyloidosis in Older Americans
.
J Card Fail
.
2016
Dec
;
22
(
12
):
996
1003
.
[PubMed]
1071-9164
43.
Yanagisawa
A
,
Ueda
M
,
Sueyoshi
T
,
Okada
T
,
Fujimoto
T
,
Ogi
Y
, et al.
Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis
.
Mod Pathol
.
2015
Feb
;
28
(
2
):
201
7
.
[PubMed]
0893-3952
44.
Aus dem Siepen
F
,
Hein
S
,
Prestel
S
,
Baumgärtner
C
,
Schönland
S
,
Hegenbart
U
, et al.
Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
Clin Res Cardiol
.
2019
Dec
;
108
(
12
):
1324
30
.
[PubMed]
1861-0684
45.
Sperry
BW
,
Reyes
BA
,
Ikram
A
,
Donnelly
JP
,
Phelan
D
,
Jaber
WA
, et al.
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
.
J Am Coll Cardiol
.
2018
Oct
;
72
(
17
):
2040
50
.
[PubMed]
0735-1097
46.
Westermark
P
. Localized amyloidoses and amyloidoses associated with aging outside the central nervous system. In: Amyloid and related disorders – surgical pathology and clinical correlations, 2nd ed. Humana Press
2015
, Ed: Picken MM, Herrera GA, Dogan A. pp 95-120.
47.
Fayyaz
AU
,
Melanie
C
,
Bois
MC
,
Dasari
S
, et al.
Amyloidosis in surgically resected atrial appendages: a study of 345 consecutive cases with clinical implications.
Mod Pathol
2019
Nov 13[EPub ahead of print]. PMID 31723241
48.
Grogg
KL
,
Aubry
MC
,
Vrana
JA
,
Theis
JD
,
Dogan
A
.
Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder
.
Am J Surg Pathol
.
2013
Mar
;
37
(
3
):
406
12
.
[PubMed]
0147-5185
49.
Flaherty
KR
,
Morgenstern
R
,
Pozniakoff
T
,
DeLuca
A
,
Castano
A
,
Maurer
MS
, et al.
99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis
.
J Nucl Cardiol
.
2019
Aug
;
•••
: ;
Epub ahead of print
.
[PubMed]
1071-3581
50.
Picken
MM
.
Modern approaches to the treatment of amyloidosis: the critical importance of early detection in surgical pathology
.
Adv Anat Pathol
.
2013
Nov
;
20
(
6
):
424
39
.
[PubMed]
1072-4109
51.
Javidiparsijani
S
,
Picken
MM
.
Should the Reporting of Bone Marrow Positivity for Amyloid Be Revised? A Critical Assessment Based On 66 Biopsies From a Single Institution
.
[Online ahead of print]
.
Arch Pathol Lab Med
.
2020
Jan
;
arpa.2019-0324-OA
.
[PubMed]
0003-9985
52.
Picken
MM
,
Herrera
GA
. Thioflavin T stain: an easier and more sensitive method for amyloid detection. In: Amyloid and related disorders – surgical pathology and clinical correlations, 2nd ed. Humana Press
2015
, Ed: Picken MM, Herrera GA, Dogan A. pp 225-227.
53.
Fine
NM
,
Arruda-Olson
AM
,
Dispenzieri
A
,
Zeldenrust
SR
,
Gertz
MA
,
Kyle
RA
, et al.
Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis
.
Am J Cardiol
.
2014
May
;
113
(
10
):
1723
7
.
[PubMed]
0002-9149
54.
Quarta
CC
,
Gonzalez-Lopez
E
,
Gilbertson
JA
,
Botcher
N
,
Rowczenio
D
,
Petrie
A
, et al.
Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis
.
Eur Heart J
.
2017
Jun
;
38
(
24
):
1905
8
.
[PubMed]
0195-668X
55.
van Gameren
II
,
Hazenberg
BP
,
Bijzet
J
,
van Rijswijk
MH
.
Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice
.
Arthritis Rheum
.
2006
Jun
;
54
(
6
):
2015
21
.
[PubMed]
0004-3591
56.
Garcia
Y
,
Collins
AB
,
Stone
JR
.
Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis
.
Hum Pathol
.
2018
Feb
;
72
:
71
9
.
[PubMed]
0046-8177
57.
Vrana
JA
,
Theis
JD
,
Dasari
S
,
Mereuta
OM
,
Dispenzieri
A
,
Zeldenrust
SR
, et al.
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics
.
Haematologica
.
2014
Jul
;
99
(
7
):
1239
47
.
[PubMed]
0390-6078
58.
Lee
JC
,
Connors
LH
,
O’Hara
CJ
. Bone Marrow Biopsy and Its Utility in the Diagnosis of AL Amyloidosis. In: Picken MM, Herrera GA, Dogan A. Amyloid and Related Disorders, Surgical Pathology and Clinical Correlations. Humana Press;
2015
, pp 343-353.
59.
Hasserjian
RP
,
Goodman
HJ
,
Lachmann
HJ
,
Muzikansky
A
,
Hawkins
PN
.
Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients
.
Histopathology
.
2007
Apr
;
50
(
5
):
567
73
.
[PubMed]
0309-0167
60.
Sungur
C
,
Sungur
A
,
Ruacan
S
,
Arik
N
,
Yasavul
U
,
Turgan
C
, et al.
Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever
.
Kidney Int
.
1993
Oct
;
44
(
4
):
834
6
.
[PubMed]
0085-2538
61.
Muchtar
E
,
Dispenzieri
A
,
Lacy
MQ
,
Buadi
FK
,
Kapoor
P
,
Hayman
SR
, et al.
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition
.
Ann Med
.
2017
Nov
;
49
(
7
):
545
51
.
[PubMed]
0785-3890
62.
Picken
MM
. Options for Amyloid Typing in Renal Pathology: The Advantages of Frozen Section Immunofluorescence and a Summary of General Recommendations Regarding Immunohistochemistry Methods. In:
Picken
, et al., editors
.
Amyloid and Related Disorders
. 2nd ed.
2015
. pp.
283
93
.
63.
Linke
RP
,
Meinel
A
,
Chalcroft
JP
. Sensitive and Reliable Immunohistochemical Typing of 21 Different Amyloid Classes in 782 Patients Using Amyloid-Type Specific Antibodies Directed Against the Amyloidotic Conformation. With Comments on the Gold Standard Debate. Amyloid
2017
, 24 (sup1), 157-158.
64.
Freudenthaler
S
,
Hegenbart
U
,
Schönland
S
,
Behrens
HM
,
Krüger
S
,
Röcken
C
.
Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients
.
Virchows Arch
.
2016
May
;
468
(
5
):
569
77
.
[PubMed]
0945-6317
65.
Dogan
A
.
Amyloidosis: insights from Proteomics
.
Annu Rev Pathol
.
2017
Jan
;
12
(
1
):
277
304
.
[PubMed]
1553-4006
66.
Lavatelli
F
,
di Fonzo
A
,
Palladini
G
,
Merlini
G
.
Systemic amyloidoses and proteomics: the state of the art
.
EuPA Open Proteom
.
2016
Feb
;
11
:
4
10
.
[PubMed]
2212-9685
67.
Picken
MM
.
Proteomics and mass spectrometry in the diagnosis of renal amyloidosis
.
Clin Kidney J
.
2015
Dec
;
8
(
6
):
665
72
.
[PubMed]
2048-8505
68.
Nasr
SH
,
Fidler
ME
,
Said
SM
.
Paraffin Immunofluorescence: A Valuable Ancillary Technique in Renal Pathology
.
Kidney Int Rep
.
2018
Jul
;
3
(
6
):
1260
6
.
[PubMed]
2468-0249
69.
Messias
NC
,
Walker
PD
,
Larsen
CP
.
Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique
.
Mod Pathol
.
2015
Jun
;
28
(
6
):
854
60
.
[PubMed]
0893-3952
70.
Gonzalez Suarez
ML
,
Zhang
P
,
Nasr
SH
,
Sathick
IJ
,
Kittanamongkolchai
W
,
Kurtin
PJ
, et al.
The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry
.
Kidney Int
.
2019
Oct
;
96
(
4
):
1005
9
.
[PubMed]
0085-2538
71.
Gilbertson
JA
,
Theis
JD
,
Vrana
JA
,
Lachmann
H
,
Wechalekar
A
,
Whelan
C
, et al.
A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue
.
J Clin Pathol
.
2015
Apr
;
68
(
4
):
314
7
.
[PubMed]
0021-9746
72.
Rezk
T
,
Gilbertson
JA
,
Mangione
PP
,
Rowczenio
D
,
Rendell
NB
,
Canetti
D
, et al.
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis
.
J Pathol Clin Res
.
2019
Jul
;
5
(
3
):
145
53
.
[PubMed]
2056-4538
73.
Abildgaard
N
,
Rojek
AM
,
Møller
HE
,
Palstrøm
NB
,
Nyvold
CG
,
Rasmussen
LM
, et al.
Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits
.
Amyloid
.
2020
Mar
;
27
(
1
):
59
66
.
[PubMed]
1350-6129
74.
Owen-Casey
MP
,
Sim
R
,
Cook
HT
,
Roufosse
CA
,
Gillmore
JD
,
Gilbertson
JA
, et al.
Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies
.
J Clin Pathol
.
2014
Aug
;
67
(
8
):
661
6
.
[PubMed]
0021-9746
75.
Sethi
S
,
Theis
JD
.
Pathology and diagnosis of renal non-AL amyloidosis
.
J Nephrol
.
2018
Jun
;
31
(
3
):
343
50
.
[PubMed]
1121-8428
76.
Lobato
L
,
Rocha
A
.
Transthyretin amyloidosis and the kidney
.
Clin J Am Soc Nephrol
.
2012
Aug
;
7
(
8
):
1337
46
.
[PubMed]
1555-9041
77.
Picken
MM
,
Dogan
A
. Amyloidoses of the kidney, the lower urinary and genital tracts (male and female), and the breast. In: Amyloid and related disorders – surgical pathology and clinical correlations, 2nd ed. Humana Press
2015
, Ed: Picken MM, Herrera GA, Dogan A. pp 369-389.
78.
Damy
T
,
Costes
B
,
Hagège
AA
,
Donal
E
,
Eicher
JC
,
Slama
M
, et al.
Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness
.
Eur Heart J
.
2016
Jun
;
37
(
23
):
1826
34
.
[PubMed]
0195-668X
79.
Milandri
A
,
Farioli
A
,
Gagliardi
C
,
Longhi
S
,
Salvi
F
,
Curti
S
, et al.
Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies
.
[Online ahead of print]
.
Eur J Heart Fail
.
2020
Jan
;
2020
(
Jan
):
23
.
[PubMed]
1388-9842
80.
Larsen
BT
,
Mereuta
OM
,
Dasari
S
,
Fayyaz
AU
,
Theis
JD
,
Vrana
JA
, et al.
Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases
.
Histopathology
.
2016
Apr
;
68
(
5
):
648
56
.
[PubMed]
0309-0167
81.
Loavenbruck
AJ
,
Singer
W
,
Mauermann
ML
,
Sandroni
P
,
B Dyck
PJ
,
Gertz
M
, et al.
Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?
Ann Neurol
.
2016
Sep
;
80
(
3
):
401
11
.
[PubMed]
0364-5134
82.
Prada
V
,
Massucco
S
,
Venturi
C
, et al.
Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases from 1981 to 2017. Front Neurol,
2018
; 10, 22 November 2019.
83.
Luigetti
M
,
Di Paolantonio
A
,
Bisogni
G
,
Romano
A
,
Conte
A
,
Barbato
F
, et al.
Sural nerve biopsy in peripheral neuropathies: 30-year experience from a single center
.
Neurol Sci
.
2020
Feb
;
41
(
2
):
341
6
.
[PubMed]
1590-1874
84.
Said
SM
,
Grogg
KL
,
Smyrk
TC
.
Gastric amyloidosis: clinicopathological correlations in 79 cases from a single institution
.
Hum Pathol
.
2015
Apr
;
46
(
4
):
491
8
.
[PubMed]
0046-8177
85.
Chandan
VS
,
Shah
SS
,
Lam-Himlin
DM
,
Petris
GD
,
Mereuta
OM
,
Dogan
A
, et al.
Globular hepatic amyloid is highly sensitive and specific for LECT2 amyloidosis
.
Am J Surg Pathol
.
2015
Apr
;
39
(
4
):
558
64
.
[PubMed]
0147-5185
86.
Baumgart
JV
,
Stuhlmann-Laeisz
C
,
Hegenbart
U
,
Nattenmüller
J
,
Schönland
S
,
Krüger
S
, et al.;
Systemic Pulmonary Amyloidosis-Impact on Diagnostics and Clinical Management
.
Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management
.
Virchows Arch
.
2018
Nov
;
473
(
5
):
627
37
.
[PubMed]
0945-6317
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.